Spinal cord stimulators have grown in popularity over the past several years as patients see benefits in the less-invasive ...

Several spine and orthopedic companies have made progress with acquisitions in the first quarter of 2025. 1. Stryker has ...

Envestnet Portfolio Solutions Inc. lifted its stake in shares of Globus Medical, Inc. (NYSE:GMED – Free Report) by 3.0% ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nevro Corp (NVRO – Research Report), Globus ...

Globus Medical GMED has experienced strong upward momentum in the past year, with its shares rising 41.8%. This has far outpaced the industry’s 7.5% decline and the S&P 500 composite’s 8.8% growth.

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.

Globus Medical, Inc. reported $657,293 million in sales and $60,275 million in operating profit for the quarter ending December 31, 2024, which was above both Wall Street’s expectations and management ...

Globus Medical GMED recently launched the COHERE ALIF Spacer, the first Porous PEEK interbody spacer for anterior lumbar interbody fusion (ALIF) surgery. Additionally, the company introduced Modulus ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

BTIG responded by raising its price target for Globus Medical shares to $94, maintaining a Buy rating, citing the company’s impressive performance and potential synergies from its recent acquisition ...